159 related articles for article (PubMed ID: 20872577)
1. SH3BP2 mutations potentiate osteoclastogenesis via PLCγ.
Lietman SA; Yin L; Levine MA
J Orthop Res; 2010 Nov; 28(11):1425-30. PubMed ID: 20872577
[TBL] [Abstract][Full Text] [Related]
2. SH3BP2 is an activator of NFAT activity and osteoclastogenesis.
Lietman SA; Yin L; Levine MA
Biochem Biophys Res Commun; 2008 Jul; 371(4):644-8. PubMed ID: 18440306
[TBL] [Abstract][Full Text] [Related]
3. SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.
Mukai T; Ishida S; Ishikawa R; Yoshitaka T; Kittaka M; Gallant R; Lin YL; Rottapel R; Brotto M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014 Dec; 29(12):2618-35. PubMed ID: 24916406
[TBL] [Abstract][Full Text] [Related]
4. Decreased SH3BP2 inhibits osteoclast differentiation and function.
Kawamoto T; Fan C; Gaivin RJ; Levine MA; Lietman SA
J Orthop Res; 2011 Oct; 29(10):1521-7. PubMed ID: 21448930
[TBL] [Abstract][Full Text] [Related]
5. SH3BP2 gain-of-function mutation exacerbates inflammation and bone loss in a murine collagen-induced arthritis model.
Mukai T; Gallant R; Ishida S; Yoshitaka T; Kittaka M; Nishida K; Fox DA; Morita Y; Ueki Y
PLoS One; 2014; 9(8):e105518. PubMed ID: 25144740
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation.
Lietman SA; Kalinchinko N; Deng X; Kohanski R; Levine MA
Hum Mutat; 2006 Jul; 27(7):717-8. PubMed ID: 16786512
[TBL] [Abstract][Full Text] [Related]
7. Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts.
Kittaka M; Mayahara K; Mukai T; Yoshimoto T; Yoshitaka T; Gorski JP; Ueki Y
J Bone Miner Res; 2018 Jan; 33(1):167-181. PubMed ID: 28914985
[TBL] [Abstract][Full Text] [Related]
8. Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties.
Wang CJ; Chen IP; Koczon-Jaremko B; Boskey AL; Ueki Y; Kuhn L; Reichenberger EJ
Bone; 2010 May; 46(5):1306-15. PubMed ID: 20117257
[TBL] [Abstract][Full Text] [Related]
9. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.
Ueki Y; Lin CY; Senoo M; Ebihara T; Agata N; Onji M; Saheki Y; Kawai T; Mukherjee PM; Reichenberger E; Olsen BR
Cell; 2007 Jan; 128(1):71-83. PubMed ID: 17218256
[TBL] [Abstract][Full Text] [Related]
10. RANKL-independent osteoclastogenesis in the SH3BP2 cherubism mice.
Kittaka M; Yoshimoto T; Hoffman H; Levitan ME; Ueki Y
Bone Rep; 2020 Jun; 12():100258. PubMed ID: 32258251
[TBL] [Abstract][Full Text] [Related]
11. Rescue of a cherubism bone marrow stromal culture phenotype by reducing TGFβ signaling.
Liu Y; Sharma T; Chen IP; Reichenberger E; Ueki Y; Arif Y; Parisi D; Maye P
Bone; 2018 Jun; 111():28-35. PubMed ID: 29530719
[TBL] [Abstract][Full Text] [Related]
12. The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism.
Kadlub N; Vazquez MP; Galmiche L; L'Herminé AC; Dainese L; Ulinski T; Fauroux B; Pavlov I; Badoual C; Marlin S; Deckert M; Leboulanger N; Berdal A; Descroix V; Picard A; Coudert AE
J Bone Miner Res; 2015 May; 30(5):878-85. PubMed ID: 25491283
[TBL] [Abstract][Full Text] [Related]
13. SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism.
Lietman SA; Prescott NL; Hicks DG; Westra WH; Levine MA
Clin Orthop Relat Res; 2007 Jun; 459():22-7. PubMed ID: 17545756
[TBL] [Abstract][Full Text] [Related]
14. 3BP2 adapter protein is required for receptor activator of NFκB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells.
GuezGuez A; Prod'homme V; Mouska X; Baudot A; Blin-Wakkach C; Rottapel R; Deckert M
J Biol Chem; 2010 Jul; 285(27):20952-63. PubMed ID: 20439986
[TBL] [Abstract][Full Text] [Related]
15. Artesunate suppresses RANKL-induced osteoclastogenesis through inhibition of PLCγ1-Ca
Zeng X; Zhang Y; Wang S; Wang K; Tao L; Zou M; Chen N; Xu J; Liu S; Li X
Biochem Pharmacol; 2017 Jan; 124():57-68. PubMed ID: 27789216
[TBL] [Abstract][Full Text] [Related]
16. NFATc1 and TNFalpha expression in giant cell lesions of the jaws.
Amaral FR; Brito JA; Perdigão PF; Carvalho VM; de Souza PE; Gomez MV; De Marco L; Gomez RS
J Oral Pathol Med; 2010 Mar; 39(3):269-74. PubMed ID: 20002873
[TBL] [Abstract][Full Text] [Related]
17. Molecular and cellular characterizations of human cherubism: disease aggressiveness depends on osteoclast differentiation.
Kadlub N; Sessiecq Q; Mandavit M; L'Hermine AC; Badoual C; Galmiche L; Berdal A; Descroix V; Picard A; Coudert AE
Orphanet J Rare Dis; 2018 Sep; 13(1):166. PubMed ID: 30236129
[TBL] [Abstract][Full Text] [Related]
18. The role of SH3BP2 in the pathophysiology of cherubism.
Reichenberger EJ; Levine MA; Olsen BR; Papadaki ME; Lietman SA
Orphanet J Rare Dis; 2012 May; 7 Suppl 1(Suppl 1):S5. PubMed ID: 22640988
[TBL] [Abstract][Full Text] [Related]
19. Cherubism gene Sh3bp2 is important for optimal bone formation, osteoblast differentiation, and function.
Mukherjee PM; Wang CJ; Chen IP; Jafarov T; Olsen BR; Ueki Y; Reichenberger EJ
Am J Orthod Dentofacial Orthop; 2010 Aug; 138(2):140.e1-140.e11; discussion 140-1. PubMed ID: 20691350
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the SH3BP2 gene mutation in cherubism.
Lee JY; Jung YS; Kim SA; Lee SH; Ahn SG; Yoon JH
Acta Med Okayama; 2008 Jun; 62(3):209-12. PubMed ID: 18596838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]